Aegon Extraordinary General Meeting approves combination of Aegon’s Dutch businesses with a.s.r.
The Hague, January 17, 2023 - Aegon N.V.'s Extraordinary Meeting of Shareholders (EGM) has today approved the strategic decision to combine Aegon’s Dutch pension, life and non-life insurance, banking, and mortgage origination operations with a.s.r. to create a leading player in the Dutch market.
As announced on October 27, 2022, the transaction with a.s.r. is expected to lead to a EUR 3.3 billion reduction in IFRS shareholders’ equity. The majority thereof will be recognized in the fourth quarter of 2022, in accordance with the applicable accounting rules. The reduction in IFRS shareholders’ equity will not impact Aegon’s solvency ratios or capacity to pay targeted dividends.
In addition to the shareholders’ approval obtained today, the closing of this transaction is subject to customary conditions, including regulatory and antitrust approvals. The works council of Aegon has rendered a positive advice in relation to the proposed transaction.
The full details of the resolution approved during the EGM can be found here.
Aegon is an integrated, diversified, international financial services group. The company offers investment, protection, and retirement solutions, with a strategic focus on three core markets (the United States, the United Kingdom, and the Netherlands), three growth markets (Spain & Portugal, Brazil, and China), and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all its activities. As a leading global investor and employer, the company seeks to have a positive impact by addressing critical environmental and societal issues, with a focus on climate change and inclusion & diversity. Aegon is headquartered in The Hague, the Netherlands, and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com.
|Media relations||Investor relations|
|Carolien van der Giessen||Jan Willem Weidema|
|+31(0) 6 11953367||+31(0) 70 344 8028|
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. In addition, any statements that refer to sustainability, environmental and social targets, commitments, goals, efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation, and expressly disclaims any duty, to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:
- Unexpected delays, difficulties, and expenses in executing against our environmental, climate, diversity and inclusion or other “ESG” targets, goals and commitments, and changes in laws or regulations affecting us, such as changes in data privacy, environmental, safety and health laws;
- Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the United Kingdom;
- Civil unrest, (geo-) political tensions, military action or other instability in a country or geographic region;
- Changes in the performance of financial markets, including emerging markets, such as with regard to:
- The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios;
- The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds;
- The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;
- Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;
- Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;
- Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries;
- The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;
- Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;
- Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;
- Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;
- Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;
- Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business;
- The frequency and severity of insured loss events;
- Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products;
- Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;
- Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;
- Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;
- Customer responsiveness to both new products and distribution channels;
- As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;
- The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;
- Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies, as well as other management initiatives related to cost savings, Cash Capital at Holding, gross financial leverage and free cash flow;
- Changes in the policies of central banks and/or governments;
- Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;
- Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;
- Consequences of an actual or potential break-up of the European monetary union in whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;
- Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers;
- Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates;
- Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); and
- Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels.
Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
SKEL fjárfestingafélag hf.: Amendment to the financial calendar and previously disclosed information4.2.2023 19:13:54 CET | Press release
The audit of SKEL’s financial statements for the year 2022, which has not been finalized, has resulted in a change of its presentation due to the company‘s transition into an investment company. Shares in subsidiaries were capitalized according to the equity method until year end 2021 but are recognised at fair value through profit or loss from the beginning of 2022. This results in a previously unrealized fair value change from 2021 of ISK 2.6 billion that was formerly accounted for directly through equity, will instead be recognised in the income statement for 2022. This change of presentation has no effect of previously announced equity for year-end 2022 of ISK 33.0-33.5 billion. Further, this does not alter the company’s ability to pay dividend. The company‘s estimated earnings net of tax will, however, increase by ISK 2.6 billion and amount to ISK 17.1-17.6 billion instead of ISK 14.5-15.0 billion as was previously announced on 31 January 2023. The company has decided to change th
City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing4.2.2023 05:18:05 CET | Press release
Vacaville high school students explore local career opportunities to honor National Career Technical Education Month VACAVILLE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- February is National Career Technical Education (CTE) Month, and the City of Vacaville joined the celebration by hosting a field trip for 58 Vacaville high school students February 3. The field trip included several locations around Vacaville and Solano County to explore advanced manufacturing and biotechnology. Every February, the Association for Career and Technical Education encourages communities to celebrate CTE Month, to raise awareness of the role that CTE has in readying learners for college and career success. This is also a time when the City of Vacaville recognizes and celebrates the contributions and achievements of community CTE partners including Solano Community College (SCC) and The Workforce Development Board of Solano County. “This field trip is an excellent opportunity for Vacaville’s young people to
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®4.2.2023 00:30:00 CET | Press release
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like abscesses that can lead to open wounds and irreversible scarring in the most intimate parts of the body2,3 There is only one approved therapy for HS and many patients, even those on treatment, still experience uncontrolled symptoms4 Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials
Maha Energy meddelar reserv- och resursrapport per 31 december 20223.2.2023 21:45:00 CET | Pressemelding
McDaniel & Associates Consultants Ltd. (“McDaniel”) har genomfört sin första utvärdering av Maha Energy AB:s (publ) (”Maha” eller ”Bolaget”) reserver och resurser. Väsentliga förändringar från föregående års reserv- och resurssiffror är hänförliga till: att den tidigare annonserade utfarmningen och Joint Operating Agreement avtalet med Mafraq Energy LLC avseende Block 70 i Oman slutförs. Maha är operatör på Block 70 och Mahas licensandel minskar till 65 procent till följd härav.att den tidigare offentliggjorda transaktionen avseende den förväntade avyttringen av Mahas brasilianska verksamhet och följaktligen bolagets olje- och gastillgångar, där försäljningsavtalet undertecknades den 27 december 2022, resulterar i att inga reserver redovisas för fälten Tie och Tartaruga. Mahas reserver1 per 31 december 2022 2022 Maha Energy AB bruttoreserver före skatt (miljoner fat)KategoriTillgångar i USAMafraqTotalt1P1,340,421,762P2,740,523,263P3,590,624,21 De huvudsakliga förändringarna i årets res
Maha Energy AB announces December 31st, 2022 Reserve Report and Resource Report3.2.2023 21:45:00 CET | Press release
McDaniel & Associates Consultants Ltd. (“McDaniel”) has completed their first annual reserve and resource determination for Maha Energy AB (publ) (“Maha” or the “Company”). Main changes from last year’s reserves and resources numbers are related to: the successful completion of the previously announced Farm Out and Joint Operating Agreement with Mafraq Energy LLC for Block 70 in Oman, in which Maha is the Operator of the block and reduces its working interest (“WI”) to 65%;The previously disclosed transaction involving the expected divestment of Maha’s Brazilian entity and, consequently, its oil and gas assets, which SPA was signed on December 27th,2022, and is why no reserves are being reported for Tie and Tartaruga fields. Maha Reserves1 as of 31st December 2022 2022 Maha Energy AB Company Gross Reserves before income tax (Million barrels)CategoryUS Assets MafraqTotal1P1.340.421.762P2.740.523.263P3.590.624.21 The main changes to this year’s reserve volumes are: A reduction of 1.0 mil